<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198480</url>
  </required_header>
  <id_info>
    <org_study_id>JMT103CN04</org_study_id>
    <nct_id>NCT04198480</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM</brief_title>
  <official_title>A Phase I/II, Single Arm, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory Hypercalcemia of Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai JMT-Bio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai JMT-Bio Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the potential of JMT103 to treat hypercalcemia of
      malignancy in patients with elevated serum calcium who do not respond to recent treatment
      with intravenous bisphosphonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/II, Single arm, Open Label, Multi-center Clinical Trial to Assess the
      Efficacy and Safety of JMT103 in Patients With refractory Hypercalcemia of Malignancy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 24, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With corrected serum calcium (CSC) ≤ 11.5 mg/dL Within 10 Days after First Dose of JMT103</measure>
    <time_frame>10 Days after First Dose of JMT103</time_frame>
    <description>Percentage of Participants With corrected serum calcium (CSC) ≤ 11.5 mg/dL Within 10 Days after First Dose of JMT103</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With corrected serum calcium (CSC) ≤ 11.5 mg/dL（2.9 mmol/L） by each visit.</measure>
    <time_frame>through study completion, an average of 57 Days</time_frame>
    <description>Percentage of Participants With corrected serum calcium (CSC) ≤ 11.5 mg/dL（2.9 mmol/L） by each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With corrected serum calcium (CSC) ≤ 10.8 mg/dL（2.7 mmol/L） by each visit.</measure>
    <time_frame>through study completion, an average of 57 Days</time_frame>
    <description>Percentage of Participants With corrected serum calcium (CSC) ≤ 10.8 mg/dL（2.7 mmol/L） by each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>through study completion, an average of 57 Days</time_frame>
    <description>Time to Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Response</measure>
    <time_frame>through study completion, an average of 57 Days</time_frame>
    <description>Time to Complete Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>through study completion, an average of 57 Days</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Corrected Serum Calcium (CSC)</measure>
    <time_frame>through study completion, an average of 57 Days</time_frame>
    <description>Change in Corrected Serum Calcium (CSC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine N-telopeptide/urine creatinine (uNTx/uCr)</measure>
    <time_frame>through study completion, an average of 57 Days</time_frame>
    <description>Change in urine N-telopeptide/urine creatinine (uNTx/uCr)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Hypercalcemia of Malignancy</condition>
  <arm_group>
    <arm_group_label>JMT103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive JMT103 at a dose of 2 mg/kg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 2 mg/kg SC on study days 8 and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JMT103</intervention_name>
    <description>2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.</description>
    <arm_group_label>JMT103</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fully informed and signed informed consent.

          2. Male or female, Adults (&gt;/=18 years).

          3. Hypercalcemia of Malignancy (HCM) as defined as documented histologically or
             cytologically confirmed cancer and a corrected serum calcium (CSC) &gt; 12.5 mg/dL (3.1
             mmol /L).

          4. Last IV bisphosphonate treatment must be &gt;/= 7 days and &lt;/= 30 days before the
             screening corrected serum calcium; or Last hydration therapy must be &gt;/= 24 hours
             before the screening corrected serum calcium（Incompatible bisphosphonate）.

          5. Adequate organ function.

        Exclusion Criteria:

          1. Pregnancy.

          2. Hyperparathyroidism, or other granulomatous disease.

          3. Hepatitis b surface antigen positive.

          4. Hepatitis c antibody positive, or HIV antibody positive.

          5. Receiving dialysis for renal failure.

          6. Known sensitivity to JMT103 composition.

          7. Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their
             window of expected therapeutic effect (as determined by the physician) prior to the
             date of screening CSC.

          8. Treatment with cinacalcet within 4 weeks prior to the date of screening CSC.

          9. Currently participating another clinical study，or Four weeks or less since receiving
             an investigational product in another clinical study.

         10. In the opinion of the investigator , being unsuitable for inclusion in the study，or
             subjects withdraw informed consent.

         11. Treatment with monoclonal antibody to RANK ligand (RANKL) within 180 days prior to the
             date of the screening CSC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin LI, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>XIUGAO YANG</last_name>
    <phone>+86-13811660565</phone>
    <email>yangxiugao@mail.ecspc.com</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraneoplastic Syndromes</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

